

JANUARY

Date	Headline and Source	Link	Summary
1 st January	Newsmaker 'Upgrade Quality or Risk Shutdowns': How India's New DCGI is Rebuilding 'Pharmacy of the World' News 18, January 01, 2024	Newsmaker 'Upgrade Quality or Risk Shutdowns': How India's New DCGI is Rebuilding 'Pharmacy of the World' - News18	According to Anil Matai, director general of the Organisation of Pharmaceutical Producers of India (OPPI) the lobby representing top foreign drugmakers including Novartis, Abbott, Sanofi and Roche CDSCO has emerged as a beacon of excellence in the regulatory landscape under the stellar leadership of Raghuvanshi.
1 st January	USV is planning to introduce nutraceuticals for enhanced diabetes care, says MD Prashant Tewari Business Today, January 01, 2024	USV is planning to introduce nutraceuticals for enhanced diabetes care, says MD Prashant Tewari	While initially invented by Novo Nordisk, Insuquick stands out as the first biosimilar of Insulin Aspart available in India. USV and BioGenomics have achieved the distinction of being the first companies in the country to secure all regulatory approvals, including completing three phases of clinical trials, prior to the product launch.
1 st January	India's cervical cancer drug, Cervavac, as efficient as global medicines: Lancet Live Mint, January 01, 2024	India's cervical cancer drug, Cervavac, as efficient as global medicines: Lancet	As of right now, India has access to two other vaccines that are licensed worldwide Cervarix, marketed by GlaxoSmithKline, and Gardasil, marketed by Merck, apart from Cervavac. Having an indigenous vaccine is a great move.
2 nd January	Global pharma majors pitch for faster approval of innovative drugs in India but CDSCO remains cautious The Print, January 02, 2024	https://theprint.in/health/global-pharma-majors-pitch-for-faster-approval-of-innovative-drugs-in-india-but-cdscs-remains-cautious/1904936/	According to the Organisation of Pharmaceutical Producers of India (OPPI), which is lobbying for the move, such approvals will help minimise the time gap between the introduction of drugs internationally and in India. OPPI represents major research-based pharmaceutical companies in India, including international giants such as Pfizer, Roche, Bayer, Merck, Novo Nordisk, and Novartis.
2 nd January	The Need for Parallel Drug Approval in India: OPPI's Urgent Plea The Health Master, January 02, 2024	The Need for Parallel Drug Approval in India: OPPI's Urgent Plea (thehealthmaster.com)	The Organisation of Pharmaceutical Producers of India (OPPI), representing major multinational pharma companies, has recently raised a crucial concern. The organization is urging the Drug Controller General India (DCGI) to facilitate parallel drug approval in India, aligning with global markets.

2 nd January	Suresh Pattathil – Managing Director & GM, AbbVie / President, OPPI Pharma Boardroom, January 2, 2023	Suresh Pattathil – Managing Director & GM, AbbVie / President, OPPI	Suresh Pattathil wears two hats within India’s vast pharma ecosystem. Not only is he responsible for managing AbbVie India as its Managing Director and GM, he also advocates for broader pharma interests as president of the Organization of Pharmaceutical Producers of India (OPPI). He speaks about India’s goal of fostering innovation and how OPPI engages with the government to promote access and advocate for fair pricing mechanisms.
3 rd January	Global pharma majors pitch for faster approval of innovative drugs in India but CDSCO remains cautious Eflip, January 03, 2024	Global pharma majors pitch for faster approval of innovative drugs in India but CDSCO remains cautious	According to the Organisation of Pharmaceutical Producers of India (OPPI), which is lobbying for the move, such approvals will help minimise the time gap between the introduction of drugs internationally and in India. OPPI represents major research-based pharmaceutical companies in India, including international giants such as Pfizer, Roche, Bayer, Merck, Novo Nordisk, and Novartis.
3 rd January	Diabetes drug semaglutide offers hope beyond obesity management kidney, heart & liver health The Print, January 03, 2024	Diabetes drug semaglutide offers hope beyond obesity management kidney, heart & liver health	The blockbuster diabetes and obesity drug semaglutide, developed by Danish pharma giant Novo Nordisk, has already emerged as a favourite among affluent sections of society in India and elsewhere. The latest finding will prompt more diabetics to go for the medication and more clinicians to consider prescribing it to their patients, Dr Anoop Misra, chairman of Fortis CDOC Hospital for Diabetes and Allied Sciences, told ThePrint.
3 rd January	From pharmacy of world, India moves to innovation in pharma The Times of India, January 03, 2024	From pharmacy of world, India moves to innovation in pharma	No longer is India just the pharmacy of the world’, manufacturing and exporting bulk drugs and affordable generic medicines, it is also now rapidly emerging as a hub of pharma innovation and digitisation, as global pharma giants home in on India for their global capability centres (GCCs). Be it mature GCCs of Danish giant Novo Nordisk and Swiss behemoth Novartis, which came up over 15 years ago, or younger ones like Roche, big pharma is counting on Indian talent to drive future growth.
4 th January	Navigating a New Era: India’s Drugs, Medical Devices, and Cosmetics Bill The Financial Express, January 04, 2024	Navigating a New Era: India’s Drugs, Medical Devices, and Cosmetics Bill	OPPI, like other stakeholders, has provided its detailed comments to the 2022 Bill. One of the concerns expressed has been its indiscriminate thrust on strict penalties. OPPI believes that in order to ensure better drug quality & patient safety, there is a need to shift the emphasis to streamlined

			regulatory processes aligned with global standards.
4 th January	AstraZeneca Gets CDSCO Panel Nod to Study anticancer drug Volrustomig Medical Dialogues, January 04, 2024	AstraZeneca Gets CDSCO Panel Nod to Study anticancer drug Volrustomig	The drug major AstraZeneca has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase III clinical trial of the Monoclonal Antibody Volrustomig.
4 th January	AstraZeneca India launches Trastuzumab deruxtecan for HER2 positive metastatic breast cancer ET Health World, January 04, 2024	AstraZeneca India launches Trastuzumab deruxtecan for HER2 positive metastatic breast cancer	AstraZeneca India Pharma Ltd officially launched Trastuzumab deruxtecan, therapy tailored for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer for those who have previously received an antiHER2 regimen.
4 th January	Glenmark cuts diabetes drug cost by 70% with first Indian biosimilar launch Business Standard, January 04, 2024	Glenmark cuts diabetes drug cost by 70% with first Indian biosimilar launch	Danish drug company Novo Nordisk's injectable prescription medicine, Victoza, is also a Liraglutide-based medication too and Glenmark s competitor in the Indian market. Victoza (3ml rDNA Liraglutide) comes in three doses: 0.6 mg, 1.2 mg, and 1.8 mg, which would last for 30 days, 15days and 10 days, respectively when administered through a pen of 6mg/ml strength (similar to Lirafit).
5 th January	Navigating the seas of change: Leadership in the age of disruption Express Pharma, January 05, 2024	Navigating the seas of change: Leadership in the age of disruption	Overall, leadership in this era of transformation requires a proactive and adaptive mindset. OPPI, as a driving force, has the unique opportunity and responsibility to shape the future of the life sciences industry. By embracing a value-driven approach, prioritising patient needs, and fostering a culture of adaptability, we not only ensure the continued success of our organisations but also contribute to the larger goal of advancing healthcare for the benefit of all.
5 th January	Learning to be nimble and efficient Blitz India, January 05, 2024	Learning to be nimble and efficient	The foreign drug companies on the other hand are loving it. One news report quoting Anil Matai, director- general of the Organisation of Pharmaceutical Producers of India (OPPI), that predominately reflects the viewpoint of the global manufacturers described the CDSCO as “a beacon of excellence in the regulatory landscape”.
5 th January	Submit Separate Toxicity Data on Indian Subject: CDSCO Panel Tells GSK on Belantamab-Mafodotin study Medical Dialogues, January 05, 2024	Submit Separate Toxicity Data on Indian Subject: CDSCO Panel Tells GSK on Belantamab-Mafodotin study	This came after the drug major GSK Pharma presented the phase I Clinical trial, protocol no. 209664. The above study is a phase 3, randomized, openlabel study of Belantamab Mafodotin administered in combination with Bortezomib, Lenalidomide, and Dexamethasone Versus Bortezomib,

			Lenalidomide and Dexamethasone alone in participants with newly diagnosed multiple myeloma who are Ineligible for Autologous Stem Cell Transplantation.
6 th January	AstraZeneca Gets CDSCO Panel Nod to Study anticancer drug DatoDXd and Durvalumab Medical Dialogues, January 06, 2024	AstraZeneca Gets CDSCO Panel Nod to Study anticancer drug DatoDXd and Durvalumab	The drug major AstraZeneca has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the phase 3 clinical study to evaluate DatoDXd and Durvalumab for neoadjuvant/adjuvant treatment of TripleNegative or Hormone Receptorlow/HER2negative Breast Cancer.
6 th January	Lupin gets tentative approval for glycemic control drugs; stock makes a Uturn after hitting 52week high Zee Biz, January 06, 2024	Lupin gets tentative approval for glycemic control drugs; stock makes a Uturn after hitting 52week high	Lupin shares on Friday clocked a 52week high on Friday after the drug maker received tentative approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for Dapagliflozin and Saxagliptin tablets to market a generic equivalent of Qtern tablets of AstraZeneca AB.
6 th January	Researchers develop new class of antibiotics to fight drug-resistant bacteria The Economic Times, January 06, 2024	Researchers develop new class of antibiotics to fight drug-resistant bacteria	The team of researchers, including those from Roche Pharma Research and Early Development, Roche Innovation Center Basel, Switzerland, and Harvard University, US, explained that the new drug worked by preventing the LPS from reaching CRAB's outer membrane by arresting the transport compound enabling the movement of the LPS.
7 th January	-	-	-
8 th January	Shifting gears. Drugmakers chart a specialised course to navigate choppy waters The Hindu Business Line, January 08, 2024	Shifting gears. Drugmakers chart a specialised course to navigate choppy waters	Looking through a regulatory lens, the industry is at an inflection point, as it makes the shift from delivering in volume to value now, says Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI), a platform largely of multinational drug companies. Conversations are centred on investments, sustaining innovation and holding the industry to higher standards of quality, given the cough syrup incidents reported from other countries.
8 th January	Roche Gets CDSCO Panel Nod to Study anticancer Drug Giredestrant for Breast Cancer Medical Dialogues, January 08, 2024	Roche Gets CDSCO Panel Nod to Study anticancer Drug Giredestrant for Breast Cancer	The drug major Roche has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the clinical trial of the anticancer drug Giredestrant compared with Fulvestrant, Palbociclib, Ribociclib, Abemaciclib.

8 th January	CDSCO Panel Grants Novartis Protocol Amendment Proposal For Alpelisib Medical Dialogues, January 08, 2024	CDSCO Panel Grants Novartis Protocol Amendment Proposal For Alpelisib	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Novartis protocol amendment proposal for the phase III clinical trial of Alpelisib (BYL719) in combination with Nabpaclitaxel in patients with advanced triple-negative breast cancer with either phosphoinositide3kinase catalytic subunit alpha (PIK3CA) mutation or Phosphate and Tension Homolog Protein (PTEN) loss without PIK3CA mutation.
9 th January	GE Healthcare elevates Nisha Srinivasan as CHRO India and South Asia People Matters, January 09, 2024	GE Healthcare elevates Nisha Srinivasan as CHRO India and South Asia	Nisha who began her stint with GE Healthcare in 2022 as a talent and organisation leader, had joined the company from Sanofi where she worked for more than 12 years in various roles. Before Sanofi, Nisha worked with ICICI Bank as HRBP for around four years.
9 th January	Little gains from FTA with EFTA after Swiss move to scrap tariffs The Financial Express, January 09, 2024	Little gains from FTA with EFTA after Swiss move to scrap tariffs	The EFTA countries request for protection of Intellectual Property Rights (IPRs) beyond normal, especially patents and copyrights in India, will conflict with India s domestic regulations. Switzerland is home to the biggest pharma and chemical companies in the world including Novartis, Roche, Bayer and Abbott.
9 th January	Justify Durvalumab dose: CDSCO Panel Tells AstraZeneca on Study of DatoDXd and Durvalumab Medical Dialogues, January 09, 2024	Justify Durvalumab dose: CDSCO Panel Tells AstraZeneca on Study of DatoDXd and Durvalumab	Reviewing the drug major AstraZeneca's Phase III clinical trial protocol of the anticancer drug of DatoDXd and Durvalumab, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has recommended the firm to submit supportive documents for the selection of Durvalumab dose of 1120mg every three weeks instead of 1500mg.
9 th January	Boehringer Ingelheim, Kyowa Kirin enter license agreement to develop novel treatment for fibroinflammatory diseases The Financial Express, January 09, 2024	Boehringer Ingelheim, Kyowa Kirin enter license agreement to develop novel treatment for fibroinflammatory diseases	Boehringer Ingelheim and Kyowa Kirin Co., Ltd. announced on Monday that they have entered into a license agreement to develop a Novel, first-in-class treatment for fibroinflammatory diseases. According to the company s press statement, the new development programme is part of Boehringer Ingelheim s commitment to combat fibroinflammatory diseases by developing breakthrough therapies, building on the company s expertise and leadership in this disease area, to improve patient outcomes.

9 th January	Novartis drug shows positive outcomes in Phase III trial for chronic myeloid leukemia treatment The Financial Express, January 09, 2024	Novartis drug shows positive outcomes in Phase III trial for chronic myeloid leukemia treatment	Novartis on Monday announced positive results in Phase III trial comparing Scemblax (asciminib) with conventional treatment in patients with chronic myeloid leukemia. According to the company's statement, ASC4FIRST is the first and only randomized head-to-head Phase III trial comparing a CML treatment vs. approved standard of care first and second generation TKIs.
10 th January	Sale of generic versions of cancer drug stops as Delhi HC prohibits patent infringement The Times of India, January 10, 2024	Sale of generic versions of cancer drug stops as Delhi HC prohibits patent infringement	The Ibrutinib patent is held by Pharmacyclics, a subsidiary of US firm AbbVie, while the drug is marketed in the country by Johnson & Johnson, an Indian affiliate of Janssen Biotech. The Ibrutinib patent is valid till 2026, and it is commercially sold under the registered trademark, Imbruvica.
10 th January	Hyderabad: Income Tax Raids At Anti-Cancer Drug Maker Gland Chemicals Over Alleged Tax Evasion Free Press Journal, January 10, 2024	Hyderabad: Income Tax Raids At Anti-Cancer Drug Maker Gland Chemicals Over Alleged Tax Evasion	Founded in 1974 by the pioneer in Heparin Technology for anticoagulants, blood thinner medication by PV Raju, Gland Chemicals manufactures active pharmaceutical ingredients (API) in Bangalore. The company expanded its operations by acquiring the Pfizer API facility in Aurangabad in February 2021 and another Pfizer formulation facility in Chennai in April 2021.
11 th January	-	-	-
12 th January	Pharma index in focus, up 3.45% YTD: Indian Pharma Market growth catches pace in December Live Mint, January 12, 2024	Pharma index in focus, up 3.45% YTD: Indian Pharma Market growth catches pace in December	In the meanwhile, during December as per Elara, as per data, Sun Pharmaceutical, Cipla, Torrent, Alkem and Glenmark grew in mid-high, single-digit percentage. Mankind Pharma, Zydus Lifesciences and Lupin grew in 10-15% range. Abbott, Ipca, Dr Reddy's and Sanofi grew slightly lower than 10%.
12 th January	Price push: Domestic pharma market grew by 6.8% in 2023, shows data Business Standard, January 12, 2024	Price push: Domestic pharma market grew by 6.8% in 2023, shows data	With an 8 per cent growth rate in the anti-infectives category, it is not surprising that GlaxoSmithKline Pharmaceuticals (GSK) Augmentin is the top-selling brand in 2023, the second year in a row. In 2023 sales of Augmentin grew 9.9 per cent to Rs 804 crore, and the volumes almost 12 per cent.
12 th January	Ojas Eye Hospital to offer ELITA SILK, introducing cutting-edge vision correction in Mumbai Hindustan Times, January 12, 2024	Ojas Eye Hospital to offer ELITA SILK, introducing cutting-edge vision correction in Mumbai	It has also recently been awarded and recognized as The Best Healthcare Brands 2023 from Economic Times. ELITA SILK by Johnson & Johnson Vision, USA is a groundbreaking advancement in vision correction, permanently removing refractive error in the eyes through a flapless, bladeless and completely safe and quick process.

12 th January	BioAsia 2024 to draw over 3k delegates The Times of India, January 12, 2024	BioAsia 2024 to draw over 3k delegates	These include keynote speakers such as Eli Lilly & Co CEO David Ricks, Bristol Myers Squibb's CEO Christopher Boerner, Medtronic chairman & CEO Geoff Martha, Nobel Laureate and Johns Hopkins School of Medicine's Prof Gregg Semenza Other top speakers include Providence president & CEO Dr Rod Hochman, Olympus CEO Stefan Kaufmann, Advent International's global operating partner Stefan Stoffel.
13 th January	Hyderabad International Convention Centre to host BioAsia summit from February 26 The New Indian Express, January 13, 2024	Hyderabad International Convention Centre to host BioAsia summit from February 26	David Ricks (CEO, Eli Lilly and Company), Christopher Boerner (Incoming CEO, Bristol Myers Squibb), Geoff Martha (Chairman and CEO, Medtronic), Gregg Semenza (Nobel Laureate and Professor at Johns Hopkins School of Medicine) and others will be the key speakers.
13 th January	Dr. Krishnan Emphasizes Backing Innovative Treatments for Enhanced Patient-Centered Kidney Care Business News This Week, January 13, 2024	Dr. Krishnan Emphasizes Backing Innovative Treatments for Enhanced Patient-Centered Kidney Care	Before joining DaVita, Dr. Krishnan served in various roles at Amgen, where he worked on medical affairs, health economics, and medical policy, and played a key role in discussions with the Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS).
13 th January	Express View on cervical cancer vaccine drive: A healthy new year The Indian Express, January 13, 2024	Express View on cervical cancer vaccine drive: A healthy new year	In 2018, the National Technical Advisory Group on Immunisation recommended the inclusion of HPV vaccines in the country's Universal Immunisation Programme (UIP). But the high costs of vaccines, then manufactured by the pharma multinationals Merck and GlaxoSmithKline, proved a deterrent the regimen costs upwards of Rs 4,000.
14 th January	2 jabs a year to keep bad cholesterol at bay breakthrough treatment to launch in India this month The Print, January 14, 2024	2 jabs a year to keep bad cholesterol at bay breakthrough treatment to launch in India this month	There is, however, a catch. At nearly Rs 1.2 lakh per jab, as revealed by the market sources, the drug Inclisiran may be unaffordable for a large number of the patients needing the therapy. Patients with high bad cholesterol would need two injections of the drug, produced by Swiss pharma giant Novartis, every year, said company sources.
15 th January	Novartis Gets CDSCO Panel nod to study antimalarial drug KLU156 with Coartem Medical Dialogues, January 15, 2024	Novartis Gets CDSCO Panel nod to study antimalarial drug KLU156 with Coartem	The drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase III clinical trial of antimalarial drug KLU156 with Coartem.
15 th January	Twice-a-year cholesterol drug	Twice-a-year cholesterol drug	Manufactured by Swiss multinational pharmaceutical Novartis and expected to cost around Rs 1.2 lakh, it has been

	Free Press Journal, January 15, 2024		approved by the Drug Controller General of India (DCGI) under the brand name of Sybrava.
16 th January	-	-	-
17 th January	Goa govt to provide advanced treatments for cancer hemophilia SMA at staterun hospital The Week, January 17, 2024	Goa govt to provide advanced treatments for cancer hemophilia SMA at staterun hospital	Goa Health Minister Vishwajit Rane on Tuesday announced the introduction of advanced treatments for critical ailments including breast cancer and hemophilia with the help of healthcare firm Roche Healthcare. Speaking at a press conference here, he said the state-run Goa Medical College and Hospital (GMCH) will administer Pertuzumab Trastuzumab combination, a monoclonal antibody specific, to second-stage breast cancer patients.
17 th January	GSK's new campaign promotes 7 star protection with 7 vaccinations for 12 yearold children Afaqs, January 17, 2024	GSK's new campaign promotes 7 star protection with 7 vaccinations for 12 yearold children	Rashmi Hegde, executive vice president, medical affairs, GlaxoSmithKline Pharmaceuticals, India, says, In the past 3 years, there have been outbreaks of certain vaccine preventable diseases such as chickenpox, measles, and flu in the country Vaccine preventable diseases not only disrupt children's health for a short time, but they have a long-term effect on their developmental milestones.
17 th January	P&G India Employees in Hyderabad Run a Marathon To Support Children With Disabilities India Education Diary, January 17, 2024	P&G India Employees in Hyderabad Run a Marathon To Support Children With Disabilities	More than 300 employees from the manufacturing plant of Procter & Gamble India (P&G India) maker of brands like Tide, Ariel etc. recently organized and participated in a marathon to support Children With Disabilities, in line with the Company's endeavor to drive inclusion for People With Disabilities.
18 th January	-	-	-
19 th January	Gujarat: Ahmedabad Gears Up For International Conference On Human Genetics Free Press Journal, January 19, 2024	Gujarat: Ahmedabad Gears Up For International Conference On Human Genetics	The four-day conference anticipates the participation of approximately 600 medical professionals from India and 150 to 200 from abroad. Notably, representatives from 36 global leaders in biotech companies, such as Sanofi, Takeda, Torrent Pharma, and Illumina Life Science, will join the discourse.
19 th January	Where to invest within the pharma theme Industry expert Kewal Handa answers The Economic Times, January 19, 2024	Where to invest within the pharma theme Industry expert Kewal Handa answers	Industry Expert pharma, says a lot of Indian companies like Sun, Zydus, and Intas are engaged in this complex generics. So the future for these companies is to have complex generics developed and to sell it in the US and global market. The other type of research that we are looking at today is in biosimilars.

19 th January	<p>WEF: India sets up alliance for global good, gender equity and equality, Mathrubhumi, January 19, 2024</p>	<p>WEF: India sets up alliance for global good, gender equity and equality.</p>	<p>The alliance has garnered support from industry leaders such as Mastercard, Uber, Tata, TVS, Bayer, Godrej, Serum Institute of India, Novartis, IMD Laussane, and over 10,000 partners from industry through CII. Supported by the Bill and Melinda Gates Foundation, the alliance will be housed and anchored by the CII Centre for Women Leadership.</p>
19 th January	<p>GSK Pharma launches campaign to create awareness on childhood vaccination The Times of India, January 19, 2024</p>	<p>GSK Pharma launches campaign to create awareness on childhood vaccination</p>	<p>GlaxoSmithKline (GSK) Pharmaceuticals has launched a multi-channel campaign to raise awareness about vaccinations that provide critical protection to children who are one to two years of age. The Indian Academy of Pediatrics (IAP) recommends seven vaccinations for children of this age group, first dose of chickenpox and hepatitis A, second dose of meningitis and MMR, booster doses of PCV and DTP Hib IPV, and annual dose of flu.</p>
19 th January	<p>Bayer and Sun Pharma sign marketing and distribution agreement for second brand of cardiac drug in India The Financial Express, January 19, 2024</p>	<p>Bayer and Sun Pharma sign marketing and distribution agreement for second brand of cardiac drug in India</p>	<p>Sun Pharmaceutical Industries Limited and Bayer on Thursday announced that both companies have signed an agreement to market and distribute a second brand of Finerenone in India. According to the company's press statement, Finerenone, a patented medicine is indicated to reduce the risk of sustained eGFR decline, endstage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes mellitus.</p>
19 th January	<p>Decade after mandate, Indian companies struggle with gender diversity; only half meeting one-woman director requirement The Economic Times, January 19, 2024</p>	<p>Decade after mandate, Indian companies struggle with gender diversity; only half meeting one-woman director requirement</p>	<p>Companies with the maximum number of women directors include: Godrej Agrovet (6), Apollo Hospitals (6), Godrej Consumer Products (6), Cummins India (5), Asian Paints (5), Colgate Palmolive (5), Piramal Enterprises (5), HCL Tech (5) and AstraZeneca's Indian arm (5). We should start a campaign that existing directors will not get their stipulated commissions in a company that does not have even one woman director, said Duggal.</p>
20 th January	<p>Budget 2024: OPPI seeks concessional tax rates for pharma players engaged in R&D Bio Voice News, January 20, 2024</p>	<p>Budget 2024: OPPI seeks concessional tax rates for pharma players engaged in R&D</p>	<p>Summary: The Organisation of Pharmaceutical Producers of India (OPPI) has sought tax rebates for the pharma and biopharma companies engaged in the research and development of innovative drugs. It has also requested for exemption of</p>

			tax duties on life saving drug imports from the union government.
20 th January	Almost all sexually active people are infected by HPV: Know about the virus India Today, January 20, 2024	Almost all sexually active people are infected by HPV: Know about the virus	In India, Cervavac is the first indigenous HPV vaccine for the prevention of cervical cancer and other HPV-associated cancers. According to a study published in The Lancet Oncology, the vaccine was found to be safe and as immunogenic as Gardasil, a quadrivalent HPV vaccine marketed by US-based Merck.
21 st January	AstraZeneca receives CDSCO approval to import and market Andexanet Alfa in India UNI India, January 21, 2024	AstraZeneca receives CDSCO approval to import and market Andexanet Alfa in India	AstraZeneca receives CDSCO approval to import and market Andexanet Alfa in India Mumbai, Jan 20 (UNI AstraZeneca Pharma India Ltd., a science-led biopharmaceutical company, announced on Saturday that it has received approval from Central Drugs Standard Control Organisation (CDSCO) in India for the import and marketing of Andexanet Alfa.
21 st January	Explained: What s Novartis new anti-cholesterol jab all about Money Control, January 21, 2024	Explained: What s Novartis new anti-cholesterol jab all about	We are happy to receive import and marketing permission for Sybrava from the Drugs Controller General of India (DCGI) office and are gearing up to launch it this month, said Amitabh Dube, Country President and Managing Director, Novartis India in an email response to Moneycontrol.
22 nd January	2 Injections A Year Can Remove Bad Cholesterol: A Quantum Leap In Preventing Heart Diseases (But, There's A Catch!) Trak, January 22, 2024	2 Injections A Year Can Remove Bad Cholesterol: A Quantum Leap In Preventing Heart Diseases (But, There's A Catch!)	Hailing it as innovational for those who suffer from atherosclerotic cardiovascular disease (ASCVD), Novartis India has already secured the approvals for importing as well as marketing the same. Notably, the exact cost of Inclisiran is not disclosed. The drug is available in the European Union since 2020 and in US and UK in 2021, currently undergoing global clinical trials in India.
23 rd January	AstraZeneca receives CDSCO approval to import and market Andexanet Alfa in India Express Pharma, January 23, 2024	AstraZeneca receives CDSCO approval to import and market Andexanet Alfa in India	AstraZeneca Pharma India has received approval from Central Drugs Standard Control Organisation (CDSCO) in India for the import and marketing of Andexanet Alfa. This treatment addresses life-threatening or refractory bleeding associated with the use of Factor Xa (FXa) inhibitors.
23 rd January	Q3 result preview: US, India to aid revenue growth for Pharma Inc Business Standard, January 23, 2024	Q3 result preview: US, India to aid revenue growth for Pharma Inc	"Among the MNCs, Sanofi is expected to report 12 per cent revenue growth in spite of divestment of brands with Y-o-Y margin improvement while Pfizer is expected to report a weak quarter. This is owing to divestment of Upjohn business and slow growth in acute-heavy portfolio," the brokerage added. As for the hospitals sector, analysts felt that on a sequential basis, the

			Ebitda margin may dip 50 bps due to pressure from ancillary business and new bed additions.
23 rd January	Leaders discuss transformational approaches shaping the pharma industry at REPharma Summit 2024 ET Health World, January 23, 2024	Leaders discuss transformational approaches shaping the pharma industry at REPharma Summit 2024	The summit commenced with a power-packed inaugural session titled Volume-to-Value in the Indian Pharmaceutical Ecosystem with Vikrant Shrotriya, Corporate Vice President & Managing Director at Novo Nordisk India Private Limited; Sukanya Choudhury, Executive Vice President Regulatory Affairs, GlaxoSmithKline and Kaushik Desai Secretary General, IPEC as moderator.
23 rd January	Novartis innovative drug shows significant positive outcomes in Phase III trial for patients with gastrointestinal cancers The Financial Express, January 23, 2024	Novartis innovative drug shows significant positive outcomes in Phase III trial for patients with gastrointestinal cancers	Pharma major Novartis on Saturday announced that its drug Lutathera has shown significantly improved patient outcomes for gastroenteropancreatic neuroendocrine tumors. According to a press statement, the company presented data from the Phase III NETTER2 trial showing that Lutathera plus long-acting release (LAR) octreotide reduced the risk of disease progression or death by 72 percent as firstline therapy in patients.
23 rd January	Pfizer Names Amit Agarwal As New CFO BW people BW People, January 23, 2024	Pfizer Names Amit Agarwal As New CFO BW people	Pfizer has named Amit Agarwal as chief financial officer. According to the stock exchange filing, Agarwal has also been appointed as an additional director (wholtime director), designated as executive director finance & chief financial officer, with a five-year term beginning 26 February 2024.
23 rd January	India's Cipla Q3 profit tops estimates on North America sales boost ET Health World, January 23, 2024	India's Cipla Q3 profit tops estimates on North America sales boost	The overall revenue for the quarter rose by 13.6%, surpassing analysts expectations of a 12% increase. Other generic drugmakers such as Dr Reddy's and Sun Pharma have also benefitted from sales of their own versions of Bristol Myers Squibb's cancer drug.
23 rd January	India denies nod to 1st ever weekly insulin for diabetics, seeks more info from maker Novo Nordisk The Print, January 23, 2024	India denies nod to 1st ever weekly insulin for diabetics, seeks more info from maker Novo Nordisk	The CDSCO decision on Icodec comes days after the Organisation of Pharmaceutical Producers of India (OPPI) a group of multinational pharma companies wrote to the CDSCO for faster approvals by granting parallel market authorisation that will allow drugs and innovative therapies to be marketed in India at the same time as in the US and Europe.
24 th January	Pharma industry expects Budget 202425 to accelerate pace of	Pharma industry expects Budget 202425 to accelerate pace of	Adding another perspective, Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI)

	innovation, R&D and digital transformation BioSpectrum India, January 24, 2024	innovation, R&D and digital transformation	said, To further support research to develop innovative pharma products, the concessional tax rates under Section 115BAB of Income Tax Act, 1961 should be extended to companies solely engaged in R&D of pharma as well, beyond those related to manufactured articles.
24 th January	Budget 2024: Pharma industry leaders urge govt for conducive policies and incentivise domestic API manufacturers The Financial Express, January 24, 2024	Budget 2024: Pharma industry leaders urge govt for conducive policies and incentivise domestic API manufacturers	To further support research to develop innovative pharma product, OPPI believes that the concessional tax rates under Section 115BAB of Income Tax Act, 1961 should be extended to companies solely engaged in R&D of pharma as well, beyond those related to manufactured articles, he said.
24 th January	Weekly insulin for diabetics; CDSCO not giving approval to drug company in India for the time being The Fourth News, January 24, 2024	Weekly insulin for diabetics; CDSCO not giving approval to drug company in India for the time being	Earlier, the Organization of Pharmaceutical Producers of India (OPPI), a consortium of multinational pharma companies, had written to the CDSCO seeking speedy approval on the issue of insulin. After this, the application was considered and permission was denied.
25 th January	Budget 2024: These companies can get the benefit of concessional tax rates CNBC TV18, January 25, 2024	Budget 2024: These companies can get the benefit of concessional tax rates	Anil Matai, Director General of Organization of Pharmaceutical Producers of India (OPPI) believes that the concessional tax rates under Section 115BAB of the Income Tax Act, 1961 should be extended to companies engaged in research and development of pharma apart from manufacturing.
25 th January	India denies nod to '1st-ever weekly insulin' for diabetics, seeks more info from maker Novo Nordisk Eflip, January 25, 2024	India denies nod to '1st-ever weekly insulin' for diabetics, seeks more info from maker Novo Nordisk	The CDSCO decision on Icodec comes days after the Organisation of Pharmaceutical Producers of India (OPPI) a group of multinational pharma companies wrote to the CDSCO for faster approvals by granting parallel market authorisation that will allow drugs and innovative therapies to be marketed in India at the same time as in the US and Europe.
26 th January	-	-	-
27 th January	Battle shifts to new class of drugs in diabetes treatment in India Business Standard, January 27, 2024	Battle shifts to new class of drugs in diabetes treatment in India	Innovator Novo Nordisk's semaglutide (Ozempic and Rybelsus) and liraglutide (Victoza) are available in India around Rs 10,000 for a monthly course (semaglutide), and Rs 5,324 for a monthly course (Liraglutide), respectively, depending on the strength the doctor prescribes. Vohra added that Cipla would try and launch the biosimilar versions of these drugs in the US as well.

27 th January	Cognizant Expands Tech Deal with Takeda to Propel Digital Transformation Initiatives Infotech Lead, January 27, 2024	Cognizant Expands Tech Deal with Takeda to Propel Digital Transformation Initiatives	Cognizant has announced the expansion of its technology agreement with Takeda, a biopharmaceutical company. The collaboration aims to bolster Takeda's digital transformation strategy by providing robust support to its technology projects.
28 th January	Can malaria vaccine rollout be scaled up? The Hindu, January 28, 2024	Can malaria vaccine rollout be scaled up?	The current rollout is part of a UNICEF initiative where the contract for the first-ever supply of a malaria vaccine was given to British multinational pharmaceutical and biotechnology company GSK with a value of up to \$170 million, according to an official release by the organisation.
29 th January	50 trials underway as drugmaker AstraZeneca eyes import of critical drugs Business Standard, January 29, 2024	50 trials underway as drugmaker AstraZeneca eyes import of critical drugs	Drugmaker AstraZeneca plans to import a range of critical drugs and is currently conducting 50 clinical trials in India. The pharma company is aiming to import Palivizumab for respiratory infections, Tremelimumab for cancer, and a Fixed Dose Combination (FDC) of Budesonide, Formoterol fumarate, Glycopyrronium for asthma combination.
29 th January	Novartis to launch two new drugs for treatment of CVDs, chronic myeloid leukaemia (CML): Amitabh Dube ET Health World, January 29, 2024	Novartis to launch two new drugs for treatment of CVDs, chronic myeloid leukaemia (CML): Amitabh Dube	Amitabh Dube, Country President and Managing Director, Novartis India, spoke to ETHealthworld's Prathiba Raju and informed that they are launching two new innovative medicines this month that have received import and marketing permission from DCGI in India. The first one is addressing an unmet need in the cardiovascular disease (CVDs) area.
29 th January	Quality Sleep: The Underestimated Ingredient To Productive & Healthy Life Free Press Journal, January 29, 2024	Quality Sleep: The Underestimated Ingredient To Productive & Healthy Life	So, tonight, when you tuck yourself into bed, remember that you are not just resting; you are giving your body the opportunity to heal, your mind the chance to grow, and your spirit the space to thrive. Embrace the power of quality sleep and watch how it transforms your life one night at a time. This article is authored by By Dr Jyotsna Arora, Scientist, Medical & Technical Affairs, ZzzQuil, P&G Health.
30 th January	-	-	-
31 st January	-	-	-
